Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Table 1 Patient baseline demographic and clinical characteristics (N = 102)

Patient characteristics	N (%)
Age
Median age, years (range)	52.5 (18–78)
< 65	87 (85.3)
≥ 65	15 (14.7)
Gender
Male	70 (68.6)
Female	32 (31.4)
ECOG PS
0	19 (18.6)
1	83 (81.4)
Prior lines of systemic therapy
1	42 (41.2)
2	34 (33.3)
3 or above	26 (25.5)
Stage of disease^#
I–II	17 (16.7)
III–IV	84 (82.4)
Pathological subtype^$
PTCL-NOS	41 (40.2)
ENKTL	23 (22.5)
ALCL ALK-	12 (11.8)
ALCL ALK+	7 (6.9)
Other subtypes*	19(18.6)
Prior therapies
Multi-agent regimen
For ENKTL
Asparaginase-based chemotherapy^†	21 (91.3)
For other subtypes of PTCL
Anthracycline-containing chemotherapy^‡	77 (97.5)
Single-agent regimen
Chidamide	24 (23.5)
Gemcitabine	55 (53.9)
Methotrexate	10 (9.8)
Bortezomib	1 (1.0)
Radiotherapy	32 (31.4)
Autologous stem-cell transplantation	7 (6.9)

ENKTL, extranodal natural killer/T cell lymphoma, nasal type; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ECOG, Eastern Cooperative Oncology Group; PS, performance status; NOS, not otherwise specified; PTCL, peripheral T cell lymphoma
^#Stage information of one case was not available
^$PTCL was pathologically diagnosed by study site pathologist for study enrolment
^*Other subtypes included: 11 cases of unclassifiable PTCL, 3 cases of type II enteropathy-associated T cell lymphoma (EATL, type II), 3 cases of mycosis fungoides (MF), 1 case of skin γ σ cutaneous T cell lymphomas (γ σ CTCL), and 1 case of primary cutaneous CD4 positive T cell lymphoma (CD4 + PCTCL)
^†The proportion (%) was defined as the number of patients receiving asparaginase-based chemotherapy divided by the number of those diagnosed with ENKTL
^‡The proportion (%) was defined as the number of patients receiving anthracycline-containing chemotherapy divided by the number of those diagnosed with other subtypes of PTCL except for ENKTL

ISSN: 1756-8722